Aster DM Quality Care shareholders approve Varun Khanna as MD and new ESOP
- All 10 postal ballot resolutions passed with requisite majority
- Varun Shadilal Khanna approved as MD and Group CEO
- New ESOP Scheme 2026 approved despite 11.25% total opposition
- Institutional investors opposed ESOP scheme with 34.69% against votes
- Managerial remuneration revisions for Azad Moopen and Alisha Moopen cleared

*this image is generated using AI for illustrative purposes only.
Aster DM Quality Care Limited shareholders approved all ten resolutions proposed in the postal ballot concluded on September 25, 2026. The approvals include the appointment of Varun Shadilal Khanna as Managing Director and Group CEO, along with a new Employee Stock Option Scheme for 2026.
The voting results were disclosed to the stock exchanges on September 26, 2026, under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scrutinizer’s report confirmed that the requisite majority was secured for both ordinary and special resolutions.
Key Appointments Approved
The most significant governance changes involve leadership restructuring and board composition. Shareholders ratified the appointment of Varun Shadilal Khanna as Managing Director and Group Chief Executive Officer. Additionally, three non-executive directors were appointed to the board:
- Ayshwarya Ravi Vikram as Non-Executive Non-Independent Director
- Ganesh Mani as Non-Executive Non-Independent Director
- Neeraj Jain, Kewal Kundanlal Handa, and Valayil Korath Mathews as Non-Executive Independent Directors
The board also approved revisions to managerial remuneration for Executive Chairman Dr. Mandayapurath Azad Moopen and Ms. Alisha Moopen, who was redesignated as Executive Director.
Voting Results Breakdown
While all resolutions passed, the margin of support varied significantly across categories. The promoter group voted unanimously in favor of all items. Public institutional investors showed notable dissent on compensation and equity-linked schemes, while retail investors largely supported management proposals.
| Resolution | Type | Votes in Favour (%) | Votes Against (%) | Outcome |
|---|---|---|---|---|
| Appointment of Varun Khanna (MD/CEO) | Ordinary | 99.27% | 0.73% | Passed |
| Appointment of Ayshwarya Ravi Vikram | Ordinary | 99.72% | 0.28% | Passed |
| Appointment of Ganesh Mani | Ordinary | 99.89% | 0.11% | Passed |
| Appointment of Neeraj Jain (Ind. Dir.) | Special | 99.33% | 0.67% | Passed |
| Appointment of Kewal K. Handa (Ind. Dir.) | Special | 99.09% | 0.91% | Passed |
| Appointment of Valayil K. Mathews (Ind. Dir.) | Special | 99.68% | 0.32% | Passed |
| Revision of Remuneration (Azad Moopen) | Special | 99.69% | 0.31% | Passed |
| Designation/Remuneration (Alisha Moopen) | Special | 94.87% | 5.13% | Passed |
| New ESOP Scheme 2026 | Special | 88.75% | 11.25% | Passed |
| Extension of ESOP Benefits to Subsidiaries | Special | 88.75% | 11.25% | Passed |
What the Numbers Show
A distinct divergence exists between retail and institutional voting patterns regarding equity incentives. While public non-institutional shareholders supported the new Employee Stock Option Scheme (ESOP) with 99.97% in favor, public institutional investors cast 34.69% of their votes against the same resolution. This resulted in an overall opposition rate of 11.25% for the ESOP scheme, significantly higher than the sub-1% opposition seen for director appointments. Similarly, the resolution regarding Alisha Moopen’s designation saw 15.82% institutional opposition, contrasting sharply with near-unanimous retail support.
Historical Stock Returns for Aster DM Quality Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.20% | -0.16% | +1.13% | +19.81% | +20.03% | +255.77% |
How will Varun Khanna's new leadership strategy impact Aster DM Quality Care's operational efficiency and market expansion plans in the coming fiscal year?
What specific governance reforms or communication strategies might management implement to address the significant institutional investor dissent regarding the new ESOP scheme?
How might the revised remuneration structure for Dr. Mandayapurath Azad Moopen and Alisha Moopen influence future compensation benchmarks within the Indian healthcare sector?


































